ARA-290 (Cibinetide) — erythropoietin fragment for tissue protection
In short
Erythropoietin peptide fragment studied in models of tissue protection and neuropathy without erythropoietic activity.
Overview
Ara 290 (Cibinetide) is an engineered 11-amino acid peptide derived from erythropoietin that activates the Innate Repair Receptor (IRR) to provide tissue-protective effects without stimulating red blood cell production. It has completed multiple Phase 2 clinical trials and holds
Activates Innate Repair Receptor (IRR) through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Brines et al. (Mol Med 2017, n=64) - 4 mg/day for 4 weeks improved neuropathic pain by 30-40% and corneal nerve fiber density by 25-30%.
Клиничните изпитвания показват отличен профил на безопасност без сериозни нежелани събития. Не са открити антитела срещу лекарството при проучвания върху хора. Липсват хемопоетични ефекти или риск от полицитемия, за разлика от еритропоетина. Противопоказан е при скорошна анти-TNF терапия (в рамките на 6 месеца) или употреба на EPO (в рамките на 2 месеца). Наблюдавайте за реакции на мястото на инжектиране и редувайте местата. Не се препоръчва по време на бременност или при пациенти с ИТМ над 34 kg/m². Признаци за спиране: Тежки реакции на мястото на инжектиране или продължително възпаление; Неочаквани промени в кръвните показатели; Признаци на алергична реакция (обрив, подуване, затруднено дишане); Влошаване на основното състояние след първоначален период на подобрение; Поява на нови неврологични симптоми; Всякакви сериозни нежелани събития, свързани с терапията.
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Brines
Phase 2 | 4 mg s.c. | 4 weeks | Pain -30-40%, nerve density +25-30%
Mol Med · 2017
View the studyInformation about ARA-290 is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadCagrilintide
Cagrilintide is a modified amylin analog developed by Novo Nordisk as a partner to semaglutide in combined incretin-amylin therapy. CagriSema (cagrilintide + semaglutide) showed 17.1% body-weight reduction in Phase 2 — a promising next step over semaglutide alone.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.
